38
FACTS AND FIGURES
NEW & NOTEWORTHY
LABORATORY & CLINICAL RESEARCH
CORE FACILITIES
EDUCATION & TRAINING
PROVIDENCE CANCER CENTER
EVENTS & ENGAGEMENT
SELECT PUBLICATIONS
LEADERSHIP
Together, Walter J. Urba, M.D., Ph.D, and Brendan D. Curti, M.D., co-direct the Providence Melanoma Program, a global leader in the development of immunotherapy for patients with melanoma. Dr. Urba and Dr. Curti have led groundbreaking international trials of immunotherapy for patients with melanoma. Dr. Urba served as principal investigator on the international trial of the checkpoint inhibitor, anti-CTLA-4, which led to FDA approval of ipilimumab – the first immunotherapeutic agent to show improved survival in patients with metastatic melanoma. They have since been actively engaged in the ongoing development of the anti-PD-1 antibodies nivolumab and pembrolizumab for patients with melanoma, serving as principal investigators or co-investigators on numerous clinical trials.
Walter J. Urba, M.D., Ph.D., member, director and endowed chair of Cancer Research; Co-director, Providence Melanoma Program (L) Brendan D. Curti, M.D., member and director, Cytokine and Adoptive Immunotherapy Program and Genitourinary Oncology Research; co-director, Providence Melanoma Program (R)
As a medical oncologist engaged in clinical research, Dr. Curti’s main focus is translational immunotherapy research. Through intramural and extramural collaborations, he is the principal investigator on numerous investigator-initiated studies that translate scientific discoveries from the laboratory to the clinic for patients with melanoma. He is a key contributor to the pre-clinical